Company Directory / Biotechnology
Public · NASDAQ:OXFDFor profitBiotechnologyAbingdon, Oxfordshire, United Kingdom
Oxford Immunotec
Oxford Immunotec, a medical diagnostics company, develops tests for various diseases based on its innovative T cell measurement technology.
- Founded
- 2002 24 years ago
- Staff
- 251-500 126 on LinkedIn
- Followers
- 12k on LinkedIn
- Funding
- $216M as listed, USD
Oxford Immunotec is now Revvity. For more information on our transformation, please visit: update.oxfordimmunotec.com/transformation
Set against six million companies
Size
251-500 people: larger than 92% of companies with a size listed. 126 people list it on LinkedIn.
Age
24 years old.
Reach
Website ranked #3,833,698 in the world for traffic, about 3k visits a month. 11,670 followers on LinkedIn.
What it does
BiotechnologyHealth CareHealth DiagnosticsTB Screening
Funding, as listed
$216M raised in total
- Rounds8
- LatestPost ipo debt, Oct 2016
- Latest amountUSD 40,000,000
- Investors15, 7 leading
What the source datasets report. We have not watched these rounds ourselves, and do not hold this company in the startups database.
Every detail we hold
Everything the source datasets list about Oxford Immunotec, field by field. Contact details are held but never shown.
The company
- Name
- Oxford Immunotec
- Type
- For profit
- Status
- Public · NASDAQ:OXFD
- Founded
- 2002
- Founders
- Peter Smith
- Industry
- Biotechnology
- Categories
- Biotechnology, Health Care, Health Diagnostics
- Specialities
- TB Screening
Where
- City
- Abingdon
- Region
- Oxfordshire
- Country
- United Kingdom
- Markets
- Europe, Middle East, and Africa (EMEA)
Size and reach
- Staff band
- 251-500
- People on LinkedIn
- 126
- LinkedIn followers
- 11,670
- Web traffic rank
- #3,833,698
- Monthly web visits
- 3,067
Funding, as listed
- Total
- $216,479,812 USD
- Rounds
- 8
- Latest round
- Post ipo debt
- Latest round date
- Oct 2016
- Latest amount
- 40,000,000 USD
- Investors
- 15
- Lead investors
- 7
- Stock listing
- NASDAQ:OXFD
- Listing status
- public
Corporate family
- Acquisitions made
- 3
About this record
- Sources
- Crunchbase, LinkedIn
- Last imported
- Sept 2026
Growth, as the source summarises it
Oxford Immunotec may be growing as the company has been active in enhancing its corporate structure and participating in significant industry events. The appointment of a new Head of Strategy and Investor Relations suggests a strategic move to strengthen its leadership, which could support future growth initiatives. Additionally, the company's involvement in the 2018 UBS Global Healthcare Conference indicates that it is engaged in the broader healthcare conversation and may be seeking opportunities for expansion or partnerships. Furthermore, Oxford Immunotec's inclusion in a report on the latent tuberculosis testing market alongside major players like Qiagen and Sanofi highlights its presence in the health diagnostics sector.
Summaries written by the source dataset, not by us, and not checked.
Companies like it
Biotechnology in United Kingdom.
From the company datasets we hold (Crunchbase, LinkedIn and Apollo listings), as listed there; 372,993 companies in United Kingdom and 5,926,251 in all. We hold no contact details for public display. Correct this, or ask for it to be removed.